MedTrace Logo

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

NCT03675724 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a pilot study to test the efficacy of the anti-inflammatory drug (Fisetin) in reducing inflammatory factors in blood in elderly adults and to test the efficacy of the drug (Fisetin) in reducing frailty and markers of inflammation, insulin resistance, and bone resorption in elderly adults.

Conditions

  • Frail Elderly Syndrome

Interventions

DIETARY_SUPPLEMENT

Fisetin

Flavonoid Family

DRUG

Placebo oral capsule

Placebo

Sponsors & Collaborators

Principal Investigators

  • Robert Pignolo, MD, PhD · Mayo Clinic

  • Sundeep Khosla, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2026-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03675724 on ClinicalTrials.gov